Oral atogepant for preventing migraines in teens
Treatments studied
Part of Brain & nervous system clinical trials.
This trial tests an oral medication called atogepant to see if it can prevent migraines in teens aged 12–17. It aims to reduce how often migraines happen and track any side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 12 and 17 years old.
- You have had chronic migraines for at least 6 months (that means headaches on 15 or more days per month, with at least 8 of those being migraines).
- In the last 28 days, you had headaches on at least 15 days and migraines on at least 8 days.
- You do not have any serious health problems, such as high blood pressure, heart disease, liver or kidney disease, or a blood disorder.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at ways to help children and teens with migraine headaches by testing a care approach that includes access to evidence-based treatment. It may help if your child has frequent migraine headaches and is starting (or not already on) certain migraine-preventive medicines.
This study tests a once-daily pill, atogepant, to see if it safely prevents chronic or episodic migraines in Korean adults. It's meant for people whose doctor has already prescribed the pill for migraine prevention.
This trial studies how well a “gepant” medicine works for different types of migraine and how tolerable it is. It may help if you have frequent migraines and you can keep a headache diary as the study asks.
This trial tests whether the cholesterol drug atorvastatin can reduce the number of migraine days in people with chronic migraine (15 or more headache days per month, including at least 8 migraine days). If you have frequent migraines and haven't tried statins before, this study may offer a new preventive option.
This study tests whether an oral medicine called atogepant can reduce migraine activity in children ages 6–17 and checks its side effects. It’s meant for kids with episodic migraine (not the more constant types) who may benefit from preventive treatment.
This trial studies the long-term safety (side effects over time) of atogepant tablets in children and teens with migraine. It may help families understand whether the medicine is safe for longer use in ages 6 to 17.
Hear when a new Chronic Migraine trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.